Effects of Alkaline Phosphatase on Renal Function in Septic Patients
Primary Purpose
Severe, Septic, Shock
Status
Completed
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
Sponsored by
About this trial
This is an interventional treatment trial for Severe focused on measuring alkaline phosphatase, sepsis, kidney function
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Proven or suspected Gram-negative bacterial infection
- Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for less than 24 h
- Acute onset of end-organ dysfunction in the preceding 12 h
Exclusion Criteria:
- Prior therapy with alkaline phosphatase
- Known allergy for cow milk
- Probable death within 24 h
- Chronic renal failure requiring hemodialysis or peritoneal dialysis
- Acute pancreatitis with no established source of infection
- HIV seropositive
- Pregnant or lactating
- Confirmed Gram-positive or fungal sepsis
- Treatment with immunosuppressants including high doses of glucocorticosteroids
Sites / Locations
- Radboud University Medical Centre
Outcomes
Primary Outcome Measures
Biomarkers of kidney damage
kidney function
markers of inflammation
Secondary Outcome Measures
Full Information
NCT ID
NCT00457613
First Posted
April 4, 2007
Last Updated
April 5, 2007
Sponsor
Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00457613
Brief Title
Effects of Alkaline Phosphatase on Renal Function in Septic Patients
Official Title
Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2006
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Radboud University Medical Center
4. Oversight
5. Study Description
Brief Summary
Septic shock is the most common cause of death in patients requiring intensive care. The kidney is one of the first organs to fail, stressing the importance to search for clinical interventions that may protect the kidneys during sepsis.
Alkaline phosphatase functions as a host defence molecule and is present in many cells and organs (e.g. intestine, placenta, liver, kidney and bone). Alkaline phosphatase has a dual mode of action. First, it binds to and, subsequently, dephosphorylates lipopolysaccharide (LPS). Second, the enzymatic reaction product monophosphoryl-LPS is a non-toxic substance for mammals which acts as a partial antagonist on the LPS receptor complex. In several animal studies, administration of alkaline phosphatase attenuates the inflammatory response and reduces mortality.
It is unknown whether these results can be extrapolated to septic patients . We studied the effects of alkaline phosphatse administration on kidney damage and function in patients with severe sepsis or septic shock.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe, Septic, Shock
Keywords
alkaline phosphatase, sepsis, kidney function
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
15 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
Primary Outcome Measure Information:
Title
Biomarkers of kidney damage
Title
kidney function
Title
markers of inflammation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Proven or suspected Gram-negative bacterial infection
Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for less than 24 h
Acute onset of end-organ dysfunction in the preceding 12 h
Exclusion Criteria:
Prior therapy with alkaline phosphatase
Known allergy for cow milk
Probable death within 24 h
Chronic renal failure requiring hemodialysis or peritoneal dialysis
Acute pancreatitis with no established source of infection
HIV seropositive
Pregnant or lactating
Confirmed Gram-positive or fungal sepsis
Treatment with immunosuppressants including high doses of glucocorticosteroids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Pickkers, MD, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Radboud University Medical Centre
City
Nijmegen
State/Province
Gelderland
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Effects of Alkaline Phosphatase on Renal Function in Septic Patients
We'll reach out to this number within 24 hrs